pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-103b-1 |
Genomic Coordinates | chr5: 168560904 - 168560965 |
Description | Homo sapiens miR-103b-1 stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases | |
pre-miRNA | hsa-mir-103b-2 |
Genomic Coordinates | chr20: 3917502 - 3917563 |
Description | Homo sapiens miR-103b-2 stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-103b | |||||||||||||||||||||
Sequence | 1| UCAUAGCCCUGUACAAUGCUGCU |23 | |||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||
Experiments | ChIP-seq | DRVs in miRNA |
|
|||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||
Putative Targets |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | GLDN | ||||||||||||||||||||
Synonyms | CLOM, COLM, CRG-L2, CRGL2, LCCS11, UNC-112 | ||||||||||||||||||||
Description | gliomedin | ||||||||||||||||||||
Transcript | NM_181789 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on GLDN | |||||||||||||||||||||
3'UTR of GLDN (miRNA target sites are highlighted) |
>GLDN|NM_181789|3'UTR 1 TGTGCTGCATTCGGCTCCCTTCAGCAAATTTCAGGGGTTTTCTGGGACCAGTTCTCCCCCAACAGGAAACTTGTTTTTTT 81 AACGTCAGCCAGATATTTAGAAAATAACCTCAAAAGTGTTTATATGGTCAGTGAGCCCCGCTTAGTGAAATAGCAACAGA 161 TTGGAAGTTGAAATGGCTGAGATTTGGTGATCTCCCCACAGCTGGCTCTGCAAGTTACCTCTTTCTCCTTGGGCCTTAGT 241 TTCCCCATTGGTAATCTGAATTGGCTAAGATGATTGGGGAGATTTTCTGTACCTGTAGGTAATTTGGTGATTCTTGGTGG 321 CTGCTCTTCTCACAACTTTTATGTATCTGCTTCTGTCGTTTAGCTTTTTTAGCCACATGCTGACCAAATTTACCTTTGAG 401 TTGATAAGTCCAGTGGCTTGAGTAGTGAATCCCTCAGTGCTGACTTATATCTTGTTCTTTGAAAAAATGCATTGACTCTT 481 TAAGACATCTAAAGTATCACATTATCCATAATTTATTGCTTTTCTTTGCATCTGCACCTGCCACCACAGAATAACCATTA 561 CCCTCAGCTGCTGATTGGGCAGCTCTGAGATTAGCAAAAGCCAGGGACAGCTACATGTTCAGGTTTTTTTTTTTTTTTTT 641 TTTTCAATAAGCTATTTTTTTTCTTTTCTTATTTTAAATAGAGAGAGAGTCTTGCTATGTTTCCCAGGCTGGTCTTGAAC 721 TCCTGGGGCTCAAGTGATCCTCCTGCCTTGGCCTCCCAAAATGCTGGATTACAGGCATGTGTGCCTGGCCCAGGTTTCTT 801 AATAAAACAGAATCATGATCTTCCAGGTTCCCCCCAGTTTCTGATCATGTTGATTTGTAGCTGTGGATCATGAACACTGA 881 ATCCTCAGATCACTCTGACTTCTTATGCTTCTCCTGTGGATCCACTATCAAAGTACTAAATGCTGTGTAAGTAGACGTTA 961 ATCTGGCTGGAACCATGGGAAGCACTTTGCAGTGTTCAGAAGAGAGGCTCCATTTGTGGCTATTATGTAGAACTGGGCCA 1041 GAGCCAGTCCATTGCCTGTTTTTTTAAATAAGGTTTTACTGAGCACAGCCACACTCATTTGTTTATGCAGTACGGCCTGA 1121 CATTGCTTTTGCTCTGCAACAGCAGAGTCGAGTCATTGCAACAAAGAGCATATGGCCCCACAGTGCCTAAAATATTGACC 1201 AGCTACCCCTTTATGGAAAAAGATTGCTGACTCCTGATAAAGAATATAAAGTGAGCCTGATTCTTGAAAAAATCAGAACC 1281 AGAGCCTGTTTTGTTTTGTTCTAAACTAAGAAGCCGCATAGGATGTGACTTGCGTTTTGAGTAGAGGGGAAGGCTGATAA 1361 CGGCGTAAGATGAAGTGGCCCTCCACAAAGGCTGGTTAGGGGACAGTTCTTTCTCTAACATAGTTTTAAAGGATGTGATC 1441 TGGTCCCCTTGGATGCCAGGAGAGAATCCAGTTGAACTTGCTCCTAAATGCTCTTAAATATGCATATTTTCTGCCAACTC 1521 ACTTCTTTAAACATCTTTCAGCCCAGCGCTGCGGCCCCGGGAAGGGCCACTGCGAATAGAGAGGAAGCTGGAAAAGTTCC 1601 TGGGGCTCTGCAGCCAGGAAGGGGAACCAGGGCAAATCTTATGTAAAGATTTTTCAGCAACTTGTCCCAATTTGTGTGTA 1681 TTCTGAAACTTTCTCTTTGGGACCAAATTCATTCTCAATGGCCCTGAGTTCAATATATTATTAACAGCAGTATTTTAAAA 1761 CTTAGGGTTGAACTGGGCATGGTGGCACATAACTGCAATCCCAGCTACTTTGGAGGCAGGGATGGGAGGATCACTTGAGG 1841 CCAGGATCTCAGGACCAGCCTAGAGAGATCCCATCTCTAAAAAATAAAATATAAGAAAATAAAACTTAGGGGATATACAG 1921 ATTTAAATATTCAAATCTCCCTGCTCCCCTGAAAGTCCCCAGGCAGCTGTCAATGACTTGTTTGTTGTGTTCTCAATATG 2001 ATGGCTATTTGAAACTTCACCTACTTTTCATTAGATTGGTTGTACCATGTCACCTTAGCTTTTAAAAATACTCTTTTCAG 2081 ATTCACGTTCTCTAACAAAGAGTCTCATGTTCAAGATCAATATGTCTAATAAGTGCTGGTGTCCTTTTAAAGTATTTAAA 2161 TATATATGTTGCTGTTGCTGAATACAGGAGACCAGGTTAGGAATATAGTTTCATAATAATAGTACATACAATACTAATTG 2241 TATATAAGGTAGCAACCAAAAGAGGTTGTTAATTAGCACATATTCCTTTTAGAAAAATGTTTCAGAAACCTCAGTCTTGA 2321 TATCTGAGCTATCTGGGCTCCCTTACTTGTGAGTAAGGGATCATGCTCACCACTGGAGAAGCTTACACCGGGACTTTTTT 2401 TCTTTTTTCTTTTTTTTTTGCTATGACAGAGTAATGCTAACGTAAGGACAACTGAGTTTGATCAGTGTTTAATCGCAGTG 2481 GGTAATCTTATCTGATTGTCTTTAAAAGTGAAAAGGATTAAGATTTTATTCTTTCTTGTAAACATTACTTGATTTTTTAA 2561 AGAAGTTTTGGGCTCACTGCTAAAATAGAGTATACAACTGAATGTTTTTAAGTCAAGATACTGTTTTAGGAGTTTACCCT 2641 CTCATTTATAACCAAAGTTGCTCTAAAACACTTTCCAAATATCTGCACTTCTGATGTCAGAATCAAACCAGATAATTCTC 2721 TAATTCTTCTTTAATCTAAAGTAGATAGCTTCCCACTGGAAAGTAAACAAAACCATCCCTCCCAACCTCAAAGCTAGGCC 2801 ACACTCTATTTCAAGGCATTTTCTTTCAGCTGATAAGGTGTCCTCCTGAAGCCAAGTAGGTGGTTCTGGTCTCCAAGTAT 2881 CGTTAAGCACAGGTGCTATGACAGAAAAAGTTCTGGGGTGGAAGTTTTAAGATGAGGAGTTCTGATCTTAGGCATCTTAA 2961 CAGTCACAAGGTGAAAAGTCAAATGAAACAGTACAATTCTTGATGAGTGAGGTGTCATCTTCCAACCACACAGAGGACGT 3041 TTTGGCTATGATCATCTGATGGCAAGTGAAGGAGAAATGAGTGATAGGGCTTTGCGTTTTCATCCAGATGCTGTGGCCCT 3121 GTGTTTCACAGCATTAAGAGCCATAATTTCCAACCTGCACAGATCCTGAACAACAAATGAATAACGATGAATGTCTTTTT 3201 GGTTGTAATTTAACAAGTCAAATAAAATAATCATTGCTGAGCACAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | LCL35 | ||||||
Disease | MIMAT0007402 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in GSM1020022. RNA binding protein: AGO2. Condition:EBV B95-8-infected
... - Skalsky RL; Corcoran DL; Gottwein E; Frank et al., 2012, PLoS pathogens. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Skalsky RL; Corcoran DL; Gottwein E; Frank et al. - PLoS pathogens, 2012
Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus linked to a number of B cell cancers and lymphoproliferative disorders. During latent infection, EBV expresses 25 viral pre-microRNAs (miRNAs) and induces the expression of specific host miRNAs, such as miR-155 and miR-21, which potentially play a role in viral oncogenesis. To date, only a limited number of EBV miRNA targets have been identified; thus, the role of EBV miRNAs in viral pathogenesis and/or lymphomagenesis is not well defined. Here, we used photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP) combined with deep sequencing and computational analysis to comprehensively examine the viral and cellular miRNA targetome in EBV strain B95-8-infected lymphoblastoid cell lines (LCLs). We identified 7,827 miRNA-interaction sites in 3,492 cellular 3'UTRs. 531 of these sites contained seed matches to viral miRNAs. 24 PAR-CLIP-identified miRNA:3'UTR interactions were confirmed by reporter assays. Our results reveal that EBV miRNAs predominantly target cellular transcripts during latent infection, thereby manipulating the host environment. Furthermore, targets of EBV miRNAs are involved in multiple cellular processes that are directly relevant to viral infection, including innate immunity, cell survival, and cell proliferation. Finally, we present evidence that myc-regulated host miRNAs from the miR-17/92 cluster can regulate latent viral gene expression. This comprehensive survey of the miRNA targetome in EBV-infected B cells represents a key step towards defining the functions of EBV-encoded miRNAs, and potentially, identifying novel therapeutic targets for EBV-associated malignancies.
LinkOut: [PMID: 22291592]
|
CLIP-seq Support 1 for dataset GSM4903833 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / CTL_TD_21_a |
Location of target site | NM_181789 | 3UTR | UGCUAUGACAGAAAAAGUUCUGGGGUGGAAGUUUUAAGAUGAGGAGUUCUGAUCUUAGGCAUCUUAACAGUCACAAGGUGAAAAGUCAAAUGAAACAGUACAAUUCUUGAUGAGUGAG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM1020022 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | LCL35 / EBV B95-8-infected, 4-thiouridine, RNase T1 |
Location of target site | ENST00000335449.6 | 3UTR | UUAAGCACAGGUGCU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22291592 / GSE41437 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
53 hsa-miR-103b Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT218386 | E2F3 | E2F transcription factor 3 | 2 | 2 | ||||||||
MIRT404221 | RPL7L1 | ribosomal protein L7 like 1 | 2 | 2 | ||||||||
MIRT441502 | SPG20 | spartin | 2 | 6 | ||||||||
MIRT444124 | ZNRF3 | zinc and ring finger 3 | 2 | 2 | ||||||||
MIRT454236 | OSBPL10 | oxysterol binding protein like 10 | 2 | 4 | ||||||||
MIRT457919 | ZNF212 | zinc finger protein 212 | 2 | 2 | ||||||||
MIRT462254 | LAMA4 | laminin subunit alpha 4 | 2 | 2 | ||||||||
MIRT463176 | ZNF281 | zinc finger protein 281 | 2 | 2 | ||||||||
MIRT472355 | TSPAN1 | tetraspanin 1 | 2 | 2 | ||||||||
MIRT474133 | LIN54 | lin-54 DREAM MuvB core complex component | 2 | 4 | ||||||||
MIRT494946 | IFFO2 | intermediate filament family orphan 2 | 2 | 2 | ||||||||
MIRT497403 | NPY4R | neuropeptide Y receptor Y4 | 2 | 2 | ||||||||
MIRT497641 | GLDN | gliomedin | 2 | 2 | ||||||||
MIRT505340 | TMEM245 | transmembrane protein 245 | 2 | 6 | ||||||||
MIRT505680 | SESTD1 | SEC14 and spectrin domain containing 1 | 2 | 6 | ||||||||
MIRT510706 | SREK1IP1 | SREK1 interacting protein 1 | 2 | 6 | ||||||||
MIRT512198 | C1orf43 | chromosome 1 open reading frame 43 | 2 | 2 | ||||||||
MIRT522089 | NUFIP2 | NUFIP2, FMR1 interacting protein 2 | 2 | 4 | ||||||||
MIRT525074 | FRK | fyn related Src family tyrosine kinase | 2 | 2 | ||||||||
MIRT531276 | PPIL3 | peptidylprolyl isomerase like 3 | 2 | 2 | ||||||||
MIRT535119 | PLXNA2 | plexin A2 | 2 | 2 | ||||||||
MIRT540836 | GNAT1 | G protein subunit alpha transducin 1 | 2 | 4 | ||||||||
MIRT541018 | WIPI2 | WD repeat domain, phosphoinositide interacting 2 | 2 | 2 | ||||||||
MIRT545752 | CA12 | carbonic anhydrase 12 | 2 | 4 | ||||||||
MIRT546404 | SRP9 | signal recognition particle 9 | 2 | 2 | ||||||||
MIRT547991 | HCFC2 | host cell factor C2 | 2 | 4 | ||||||||
MIRT554502 | SAE1 | SUMO1 activating enzyme subunit 1 | 2 | 2 | ||||||||
MIRT558360 | DMTF1 | cyclin D binding myb like transcription factor 1 | 2 | 2 | ||||||||
MIRT558863 | CD2AP | CD2 associated protein | 2 | 2 | ||||||||
MIRT559939 | ZNF567 | zinc finger protein 567 | 2 | 2 | ||||||||
MIRT566300 | PPM1A | protein phosphatase, Mg2+/Mn2+ dependent 1A | 2 | 2 | ||||||||
MIRT567490 | FOXK1 | forkhead box K1 | 2 | 2 | ||||||||
MIRT617139 | ZNF556 | zinc finger protein 556 | 2 | 2 | ||||||||
MIRT625400 | AKR7L | aldo-keto reductase family 7 like (gene/pseudogene) | 2 | 2 | ||||||||
MIRT626491 | CEP89 | centrosomal protein 89 | 2 | 2 | ||||||||
MIRT629487 | GSN | gelsolin | 2 | 4 | ||||||||
MIRT638456 | PLXDC2 | plexin domain containing 2 | 2 | 2 | ||||||||
MIRT648498 | CMBL | carboxymethylenebutenolidase homolog | 2 | 2 | ||||||||
MIRT654845 | PPM1L | protein phosphatase, Mg2+/Mn2+ dependent 1L | 2 | 2 | ||||||||
MIRT664587 | HSD17B12 | hydroxysteroid 17-beta dehydrogenase 12 | 2 | 2 | ||||||||
MIRT664977 | TDRD1 | tudor domain containing 1 | 2 | 2 | ||||||||
MIRT665028 | ELK1 | ELK1, ETS transcription factor | 2 | 2 | ||||||||
MIRT666043 | STON2 | stonin 2 | 2 | 2 | ||||||||
MIRT668863 | CRY2 | cryptochrome circadian clock 2 | 2 | 2 | ||||||||
MIRT669297 | C17orf85 | nuclear cap binding subunit 3 | 2 | 2 | ||||||||
MIRT680975 | DCAF17 | DDB1 and CUL4 associated factor 17 | 2 | 2 | ||||||||
MIRT682267 | RS1 | retinoschisin 1 | 2 | 2 | ||||||||
MIRT685283 | KIAA1143 | KIAA1143 | 2 | 2 | ||||||||
MIRT693375 | PIGP | phosphatidylinositol glycan anchor biosynthesis class P | 2 | 2 | ||||||||
MIRT701785 | MSL1 | male specific lethal 1 homolog | 2 | 2 | ||||||||
MIRT709373 | SPECC1 | sperm antigen with calponin homology and coiled-coil domains 1 | 2 | 2 | ||||||||
MIRT715154 | IL12B | interleukin 12B | 2 | 2 | ||||||||
MIRT734499 | ADAMTS5 | ADAM metallopeptidase with thrombospondin type 1 motif 5 | 3 | 0 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|